{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:04:30Z","timestamp":1767830670218,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40271-017-0285-1","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T07:03:29Z","timestamp":1511247809000},"page":"329-340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7716-8819","authenticated-orcid":false,"given":"Tomas","family":"Mlcoch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7182-4010","authenticated-orcid":false,"given":"Jan","family":"Tuzil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Sedova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Stolfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Urbanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Suchy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Smrzova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jitka","family":"Jircikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tereza","family":"Hrnciarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Dolezal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,21]]},"reference":[{"key":"285_CR1","unstructured":"Gossec L, Smolen JS, Ramiro S, Wit M de, Cutolo M, Dougados M, et al. European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases. 2015 Dec 7 (Annrheumdis-2015-208337)."},{"issue":"4","key":"285_CR2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5312\/wjo.v5.i4.537","volume":"5","author":"J-T Liu","year":"2014","unstructured":"Liu J-T, Yeh H-M, Liu S-Y, Chen K-T. Psoriatic arthritis: Epidemiology, diagnosis, and treatment. World J Orthop. 2014;5(4):537\u201343.","journal-title":"World J Orthop."},{"issue":"4","key":"285_CR3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545\u201368.","journal-title":"Rheum Dis Clin North Am."},{"key":"285_CR4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13075-017-1265-5","volume":"19","author":"M Bergman","year":"2017","unstructured":"Bergman M, Lundholm A. Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis. Arthritis Res Therapy. 2017;19:63.","journal-title":"Arthritis Res Therapy."},{"issue":"4 Suppl 73","key":"285_CR5","first-page":"S126","volume":"30","author":"PA Cortesi","year":"2012","unstructured":"Cortesi PA, Scalone L, D\u2019Angiolella L, Belisari A, Fusco F, Olivieri I, et al. Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S126\u201331.","journal-title":"Clin Exp Rheumatol."},{"issue":"5","key":"285_CR6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3899\/jrheum.130797","volume":"41","author":"E McDonough","year":"2014","unstructured":"McDonough E, Ayearst R, Eder L, Chandran V, Rosen CF, Thavaneswaran A, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41(5):887\u201396.","journal-title":"J Rheumatol."},{"issue":"6","key":"285_CR7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4103\/2229-5178.193908","volume":"7","author":"R Sarkar","year":"2016","unstructured":"Sarkar R, Chugh S, Bansal S. General measures and quality of life issues in psoriasis. Indian Dermatol Online J. 2016;7(6):481.","journal-title":"Indian Dermatol Online J."},{"key":"285_CR8","first-page":"1","volume":"24","author":"T Mlcoch","year":"2016","unstructured":"Mlcoch T, Sedova L, Stolfa J, Urbanova M, Suchy D, Smrzova A, et al. Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis. Expert Rev Pharmacoecon Outcomes Res. 2016;24:1\u20139.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"285_CR9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.vhri.2014.07.008","volume":"4","author":"K Kruntor\u00e1dov\u00e1","year":"2014","unstructured":"Kruntor\u00e1dov\u00e1 K, Klime\u0161 J, \u0160edov\u00e1 L, \u0160tolfa J, Dole\u017eal T, Pet\u0159\u00edkov\u00e1 A. Work productivity and costs related to patients with ankylosing spondylitis, rheumatoid arthritis, and psoriasis. Value in Health Reg Issues. 2014;4:100\u20136.","journal-title":"Value in Health Reg Issues."},{"issue":"2","key":"285_CR10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3899\/jrheum.160180","volume":"44","author":"T Gudu","year":"2017","unstructured":"Gudu T, Kiltz U, de Wit M, Kvien TK, Gossec L. Mapping the effect of psoriatic arthritis using the international classification of functioning, disability Health. J Rheumatol. 2017;44(2):193\u2013200.","journal-title":"J Rheumatol."},{"issue":"4","key":"285_CR11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40271-017-0221-4","volume":"10","author":"E Dures","year":"2017","unstructured":"Dures E, Hewlett S, Lord J, Bowen C, McHugh N, Group F the PS, et al. Important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study. Patient. 2017;10(4):455\u201362.","journal-title":"Patient."},{"key":"285_CR12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.vhri.2014.07.004","volume":"4","author":"J Klime\u0161","year":"2014","unstructured":"Klime\u0161 J, Vocelka M, \u0160edov\u00e1 L, Dole\u017eal T, Ml\u010doch T, Pet\u0159\u00edkov\u00e1 A, et al. Medical and Productivity costs of rheumatoid arthritis in The Czech Republic: cost-of-illness study based on disease severity. Value in Health Reg Issues. 2014;4:75\u201381.","journal-title":"Value in Health Reg Issues."},{"issue":"8","key":"285_CR13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40273-013-0069-y","volume":"31","author":"B Kearns","year":"2013","unstructured":"Kearns B, Ara R, Wailoo A, Manca A, Alava MH, Abrams K, et al. Good practice guidelines for the use of statistical regression models in economic evaluations. Pharmacoeconomics. 2013;31(8):643\u201352.","journal-title":"Pharmacoeconomics."},{"issue":"2","key":"285_CR14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10198-009-0168-z","volume":"11","author":"JE Brazier","year":"2010","unstructured":"Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215\u201325.","journal-title":"Eur J Health Econ."},{"issue":"1","key":"285_CR15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40273-015-0328-1","volume":"34","author":"E Heintz","year":"2016","unstructured":"Heintz E, Gerber-Grote A, Ghabri S, et al. Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries. PharmacoEconomics. 2016;34(1):59\u201376.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"285_CR16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10198-015-0759-9","volume":"18","author":"T Ml\u010doch","year":"2017","unstructured":"Ml\u010doch T, Klime\u0161 J, Fila L, V\u00e1vrov\u00e1 V, Skalick\u00e1 V, Turnovec M, et al. Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study. Eur J Health Econ. 2017;18(1):73\u201382.","journal-title":"Eur J Health Econ."},{"key":"285_CR17","first-page":"501","volume-title":"Variance components","author":"SR Searle","year":"2006","unstructured":"Searle SR, Casella G, McCulloch CE. Variance components. Hoboken: Wiley; 2006. p. 501 (Wiley series in probability and statistics)."},{"issue":"20","key":"285_CR18","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E","volume":"16","author":"A Cnaan","year":"1997","unstructured":"Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med. 1997;16(20):2349\u201380.","journal-title":"Stat Med."},{"issue":"11","key":"285_CR19","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z","volume":"17","author":"P Burton","year":"1998","unstructured":"Burton P, Gurrin L, Sly P. Extending the simple linear regression model to account for correlated responses: an introduction to generalized estimating equations and multi-level mixed modelling. Stat Med. 1998;17(11):1261\u201391.","journal-title":"Stat Med."},{"issue":"4","key":"285_CR20","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3899\/jrheum.131250","volume":"41","author":"LC Coates","year":"2014","unstructured":"Coates LC, FitzGerald O, Mease PJ, Gladman DD, Strand V, Goel N, et al. Development of a disease activity and responder index for psoriatic arthritis\u2013report of the Psoriatic Arthritis Module at OMERACT 11. J Rheumatol. 2014;41(4):782\u201391.","journal-title":"J Rheumatol."},{"issue":"Suppl 1","key":"285_CR21","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/s10198-014-0592-6","volume":"15","author":"M P\u00e9ntek","year":"2014","unstructured":"P\u00e9ntek M, Po\u00f3r G, Wiland P, Olej\u00e1rov\u00e1 M, Brzosko M, Codreanu C, et al. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries. Eur J Health Econ. 2014;15(Suppl 1):S35\u201343.","journal-title":"Eur J Health Econ."},{"issue":"1","key":"285_CR22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jval.2016.11.006","volume":"20","author":"AJ Wailoo","year":"2017","unstructured":"Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: An ISPOR good practices for outcomes research task force report. Value Health. 2017;20(1):18\u201327.","journal-title":"Value Health."},{"issue":"10","key":"285_CR23","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40273-015-0312-9","volume":"33","author":"S Petrou","year":"2015","unstructured":"Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, et al. The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. PharmacoEconomics. 2015;33(10):993\u20131011.","journal-title":"PharmacoEconomics."},{"issue":"6","key":"285_CR24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","volume":"19","author":"SE Wolowacz","year":"2016","unstructured":"Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016;19(6):704\u201319.","journal-title":"Value Health."},{"issue":"8","key":"285_CR25","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"285_CR26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JMH Moll","year":"1973","unstructured":"Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheumatism. 1973;3(1):55\u201378.","journal-title":"Semin Arthritis Rheumatism."},{"key":"285_CR27","unstructured":"Aletaha D, Funovits J, Schoels M, Kavanaugh A, Baker D, Smolen J. A simple additive disease activity index for psoriatic arthritis: first evaluations of clinical validity. In: Vol 58. Wiley-Blackwell commerce place, 350 main st, Malden 02148, MA USA; 2008:S201\u2013S202."},{"issue":"5 Suppl 93","key":"285_CR28","first-page":"S48","volume":"33","author":"JS Smolen","year":"2015","unstructured":"Smolen JS, Schoels M, Aletaha D. Disease activity and response assessment in psoriatic arthritis using the disease activity index for PSoriatic arthritis (DAPSA). A brief review. Clin Exp Rheumatol. 2015;33(5 Suppl 93):S48\u201350.","journal-title":"Clin Exp Rheumatol."},{"issue":"Suppl3","key":"285_CR29","first-page":"700","volume":"69","author":"J \u0160tolfa","year":"2010","unstructured":"\u0160tolfa J, \u0160edov\u00e1 L. A contribution to the development of a composite disease activity index for patients with psoriatic arthritis (DAPA). Ann Rheum Dis. 2010;69(Suppl3):700.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"285_CR30","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811\u20138.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"285_CR31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RGB Langley","year":"2015","unstructured":"Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point investigator\u2019s global assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26(1):23\u201331.","journal-title":"J Dermatol Treat."},{"issue":"5 Suppl 39","key":"285_CR32","first-page":"S14","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce B, Fries JF. The health assessment questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(5 Suppl 39):S14\u20138.","journal-title":"Clin Exp Rheumatol."},{"issue":"1","key":"285_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53\u201372.","journal-title":"Health Policy."},{"key":"285_CR34","unstructured":"EQ-5D value sets: inventory, comparative review and user guide | Agota Szende | Springer, Berlin. \n                        http:\/\/www.springer.com\/gp\/book\/9781402055102\n                        \n                    . [Internet]. [cited 2017 Apr 13]."},{"key":"285_CR35","unstructured":"\u010cFES. Doporu\u010den\u00e9 postupy \u010cesk\u00e9 farmakoekonomick\u00e9 spole\u010dnosti (\u010cFES) pro zdravotn\u011b-ekonomick\u00e1 hodnocen\u00ed v \u010cR, Czech Pharmacoeconomic Society. 2016."},{"key":"285_CR36","unstructured":"SUKL. Postup pro posuzov\u00e1n\u00ed anal\u00fdzy n\u00e1kladov\u00e9 efektivity, State Institute for Drug Control. 2017."},{"issue":"2","key":"285_CR37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11136-013-0496-4","volume":"23","author":"K Burstr\u00f6m","year":"2014","unstructured":"Burstr\u00f6m K, Sun S, Gerdtham U-G, Henriksson M, Johannesson M, Levin L-\u00c5, et al. Swedish experience-based value sets for EQ-5D health states. Qual Life Res. 2014;23(2):431\u201342.","journal-title":"Qual Life Res."},{"issue":"5","key":"285_CR38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics."},{"issue":"1","key":"285_CR39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0272989X11416988","volume":"32","author":"A Basu","year":"2012","unstructured":"Basu A, Manca A. Regression estimators for generic health-related quality of life and quality-adjusted life years. Med Decis Making. 2012;32(1):56\u201369.","journal-title":"Med Decis Making."},{"key":"285_CR40","volume-title":"Encyclopedia of biostatistics","author":"CE McCulloch","year":"2005","unstructured":"McCulloch CE, Neuhaus JM. Generalized linear mixed models. In: Armitage P, Colton T, editors. Encyclopedia of biostatistics. New York: Wiley; 2005."},{"key":"285_CR41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/OARRR.S56073","volume":"9","author":"S D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo S, Tramontano G, Gilio M, Leccese P, Olivieri I. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol. 2017;9:21\u20138.","journal-title":"Open Access Rheumatol."},{"issue":"2","key":"285_CR42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.2041-210x.2012.00261.x","volume":"4","author":"S Nakagawa","year":"2013","unstructured":"Nakagawa S, Schielzeth H. A general and simple method for obtaining R2 from generalized linear mixed-effects models. Methods Ecol Evol. 2013;4(2):133\u201342.","journal-title":"Methods Ecol Evol."},{"key":"285_CR43","unstructured":"Ustekinumab for treating active psoriatic arthritis. |Guidance and guidelines| NICE. \n                        https:\/\/www.nice.org.uk\/guidance\/ta340\n                        \n                    . Accessed 15 May 2017."},{"key":"285_CR44","unstructured":"Apremilast for treating active psoriatic arthritis |Guidance and guidelines| NICE. \n                        https:\/\/www.nice.org.uk\/guidance\/ta433\n                        \n                    . Accessed 15 May 2017."},{"key":"285_CR45","unstructured":"Psoriatic arthritis\u2014certolizumab pegol and secukinumab (after DMARDs) [ID579] | Guidance and guidelines | NICE. \n                        https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-tag521\n                        \n                    . Accessed 15 May 2017."},{"issue":"6","key":"285_CR46","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jclinepi.2006.09.006","volume":"60","author":"CA Marra","year":"2007","unstructured":"Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, et al. Not all \u201cquality-adjusted life years\u201d are equal. J Clin Epidemiol. 2007;60(6):616\u201324.","journal-title":"J Clin Epidemiol."},{"issue":"1","key":"285_CR47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1590\/S0482-50042010000100004","volume":"50","author":"MI Corbacho","year":"2010","unstructured":"Corbacho MI, Dapueto JJ. Assessing the functional status and quality of life of patients with rheumatoid arthritis. Rev Bras Reumatol. 2010;50(1):31\u201343.","journal-title":"Rev Bras Reumatol."},{"issue":"14","key":"285_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15140","volume":"15","author":"K Malottki","year":"2011","unstructured":"Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess. 2011;15(14):1\u2013278.","journal-title":"Health Technol Assess."},{"key":"285_CR49","unstructured":"Ducournau P, Kielhorn A, Wintfeld N. Comparison of linear and non-linear utility mapping between HAQ and EQ-5D using pooled data from the tocilizumab trials OPTION and LITHE. Annu Meet Br Soc Rheumatol. 2009;2009:258."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-017-0285-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-017-0285-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-017-0285-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,11]],"date-time":"2018-05-11T00:23:07Z","timestamp":1525998187000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-017-0285-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,21]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1007\/s40271-017-0285-1","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,21]]}}}